Featured Research

from universities, journals, and other organizations

New drug could help maintain long-term weight loss

Date:
July 26, 2012
Source:
Cell Press
Summary:
A new drug could aid in losing weight and keeping it off. The drug increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.

A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although so far the new drug has only been tested on mice, the findings have implications for the development of new treatments for obesity in humans.

"By sensitizing the body to naturally occurring leptin, the new drug could not only promote weight loss, but also help maintain it," says senior study author George Kunos of the National Institute on Alcohol Abuse and Alcoholism. "This finding bodes well for the development of a new class of compounds for the treatment of obesity and its metabolic consequences."

Although leptin is an appetite suppressant, leptin supplements alone have not been effective at reducing body weight in humans. It's thought that this is because of desensitization to the hormone; leptin is still there, but our bodies can no longer respond to it. While it is not entirely clear how this desensitization occurs, cannabinoid receptors, which mediate the feelings of hunger produced by marijuana and naturally occurring cannabinoids in the body, are thought to be involved. So blocking these receptors, rather than providing excess leptin, could be more effective at long-term weight loss. Knowing that marijuana use causes the munchies, scientists had developed anti-obesity drugs that target cannabinoid receptor type 1 (CB1R). One CB1R-binding drug called rimonabant was sold in Europe beginning in 2006, but it was taken off the market a few years later due to serious psychiatric side effects, including anxiety, depression and thoughts of suicide.

To minimize these side effects, Kunos and his team previously developed a CB1R-targeting drug that did not enter the brain as easily as rimonabant. However, the drug was not as effective at reducing weight and improving metabolic health, possibly because of its specific mode of action. In the new study, Kunos tested a new compound, JD5037, that targets CB1R without penetrating the brain. JD5037suppressed the appetite of obese mice, caused weight loss, and even improved metabolic health, in part by resensitizing mice to the appetite-suppressing hormone leptin. Importantly, the mice did not show signs of anxiety or other behavioral side effects.

"Obesity is a growing public health problem, and there is a strong need for new types of medications to treat obesity and its serous metabolic complications, including diabetes and fatty liver disease," says Kunos.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Joseph Tam, Resat Cinar, Jie Liu, Grzegorz Godlewski, Daniel Wesley, Tony Jourdan, Gergő Szanda, Bani Mukhopadhyay, Lee Chedester, Jeih-San Liow, RobertB. Innis, Kejun Cheng, KennerC. Rice, JeffreyR. Deschamps, RobertJ. Chorvat, JohnF. McElroy, George Kunos. Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance. Cell Metabolism, 2012; DOI: 10.1016/j.cmet.2012.07.002

Cite This Page:

Cell Press. "New drug could help maintain long-term weight loss." ScienceDaily. ScienceDaily, 26 July 2012. <www.sciencedaily.com/releases/2012/07/120726122116.htm>.
Cell Press. (2012, July 26). New drug could help maintain long-term weight loss. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2012/07/120726122116.htm
Cell Press. "New drug could help maintain long-term weight loss." ScienceDaily. www.sciencedaily.com/releases/2012/07/120726122116.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins